Información del producto
Nombre:Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate
Marca:Biosynth
Descripción:Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate (SNX-111) is a novel, orally active, nonselective inhibitor of the enzyme diacylglycerol acyltransferase 2 (DGAT2). SNX-111 is in development for the treatment of lipid metabolism disorders and as an adjunct to diet and exercise. In a study of patients with hyperlipidaemia and type 2 diabetes mellitus, SNX-111 was found to reduce serum triglycerides and cholesterol levels. SNX-111 also reduced blood sugar levels in diabetic patients with elevated blood sugar levels.
SNX-111 has been shown to be well tolerated in short term clinical trials for up to 12 weeks. The most common side effects were headache, diarrhoea, nausea, vomiting and abdominal pain.
SNX-111 has been shown to be well tolerated in short term clinical trials for up to 12 weeks. The most common side effects were headache, diarrhoea, nausea, vomiting and abdominal pain.
Aviso:Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Propiedades químicas
Peso molecular:229.17 g/mol
Fórmula:C9H8N3NaO3
Pureza:Min. 95%